Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829511 | 0.81 | ALDH1A1 (0.65) | NSD2DRD2FLT3ALDH1A1IRAK4 | |
| SCHEMBL7239764 | 0.79 | NOTUM (0.46) | NSD2DRD2ALDH1A1NOTUMDRD3 | |
| SCHEMBL2923261 | 0.79 | PLK1 (0.43) | NSD2DRD2FLT3ALDH1A1IRAK4 | |
| SCHEMBL1013253 | 0.79 | CYP1A2 (0.61) | ALDH1A1GAANPC1NFKB1RAB9A | |
| SCHEMBL2083398 | 0.78 | MAP3K7 (0.43) | NSD2DRD2FLT3ALDH1A1IRAK4 | |
| SCHEMBL23558108 | 0.74 | SMN1; SMN2 (0.59) | NSD2DRD2FLT3ALDH1A1NOTUM | |
| SCHEMBL11519310 | 0.73 | CA1 (0.44) | DRD2ALDH1A1NPC1NFKB1RAB9A | |
| SCHEMBL19086932 | 0.72 | MAPT (0.45) | NSD2DRD2FLT3ALDH1A1NOTUM | |
| SCHEMBL2474225 | 0.71 | RAB9A (0.58) | ALDH1A1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL4667093 | 0.71 | RAB9A (0.43) | ALDH1A1NPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| CN-101878031-A | The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-11-03 | — | — | CN | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | NSD2 3006/4885DRD2 3672/4885FLT3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.